Detalhe da pesquisa
1.
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
Blood;
140(23): 2443-2450, 2022 12 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35772005
2.
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation.
Am J Hematol;
99(6): 1205-1207, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38602288
3.
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.
Br J Haematol;
193(6): 1213-1219, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33997961
4.
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.
Br J Haematol;
189(6): 1074-1082, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32108328
5.
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Am J Hematol;
94(4): 439-445, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30663805
6.
Daratumumab proves safe and highly effective in AL amyloidosis.
Br J Haematol;
185(2): 342-344, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29938774
7.
Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series.
Ann Hematol;
98(10): 2457-2459, 2019 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31392460
8.
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Am J Hematol;
89(4): 349-54, 2014 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24273135
9.
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Blood Cancer J;
14(1): 90, 2024 May 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38821914
10.
JADPRO Live 2022: Reaching the Peak of Practice.
J Adv Pract Oncol;
14(3): 189-190, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37197722
11.
Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology.
J Adv Pract Oncol;
14(3): 223-226, 2023 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37197733
12.
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.
Cancers (Basel);
15(7)2023 Apr 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37046821
13.
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
J Clin Med;
12(17)2023 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37685606
14.
JADPRO Live Virtual 2021: New Paths to Patient Care.
J Adv Pract Oncol;
13(3): 188-189, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35663161
15.
A Call to Action: The Role of the Oncology AP in Equitable Cancer Care.
J Adv Pract Oncol;
13(3): 213-216, 2022 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35663178
16.
A Focus on Special Populations in Relapsed Multiple Myeloma.
J Adv Pract Oncol;
13(Suppl 4): 23-30, 2022 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35937464
17.
A Focus on Relapsed Multiple Myeloma.
J Adv Pract Oncol;
13(Suppl 4): 15-21, 2022 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35937465
18.
A Focus on Newly Diagnosed Multiple Myeloma.
J Adv Pract Oncol;
13(Suppl 4): 7-14, 2022 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35937466
19.
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma.
J Adv Pract Oncol;
13(Suppl 4): 31-43, 2022 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35937467
20.
JADPRO Live Virtual 2020: Learning Today, Leading Tomorrow.
J Adv Pract Oncol;
12(3): 236-237, 2021 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34084564